| | Making a difference Echo Therapeutics is a transdermal medical device and specialty pharmaceuticals company. Echo's Symphony tCGM System is a next-generation,  non-invasive (needle-free),  wireless, transdermal continuous glucose monitoring (tCGM) system focused on changing the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care markets. Echo's AzoneTS transdermal drug reformulation technology is focused on building a pipeline of safer and improved versions of widely-prescribed, FDA-approved specialty pharmaceutical products. Echo is developing most of its AzoneTS pipeline in accordance with the FDA's Section 505(b)(2) guidelines. Durhalieve, Echo's lead AzoneTS durg candidate, is an advanced topical reformulation of triamcinolone acetonide for treatment of corticosteroid responsive dermatoses. Echo has submitted its Durhalieve New Drug Application (NDA) to the FDA . on April 18, 2008 15:59:42 by (69.236.165.10) Copyright © echo therapeutics Powered by
